Table 1.

Patient Demographic and Clinical Characteristics

Characteristic	Total (N = 249)		O3-FA Arm (n = 122)		Placebo Arm (n = 127)
	No.	%	No.	%	No.	%
Age, years
Median	59.2		59.5		59.1
Hispanic ethnicity
Yes	16	6	7	6	9	7
No	225	90	112	92	113	89
Unknown	8	3	3	2	5	4
Race
White	217	87	113	93	104	82
Black*	20	8	5	4	15	12
Asian	4	2	1	1	3	2
Native American	1	< 1	0	0	1	1
Multiracial	2	1	1	1	1	1
Unknown	5	2	2	2	3	2
Osteoarthritis
Yes	57	23	28	23	29	23
No	192	77	94	77	98	77
Prior taxane
Yes	144	58	71	58	73	57
No	105	42	51	42	54	43
Location of joint pain*†
Knee	178	71	87	69	91	75
Hand	169	68	90	71	79	65
Ankle	91	37	34	27	57	47
Wrist	84	34	38	30	46	38
Shoulder	97	39	51	40	46	38
Other	130	52	65	51	65	53
Self-reported comorbid conditions
Diabetes	32	13	19	15	13	11
Hypertension	101	41	48	38	53	43
High cholesterol	77	31	45	35	32	26
Heart disease	13	5	9	7	4	3
AI
Anastrozole	146	59	73	57	73	60
Exemestane	29	12	14	11	15	12
Letrozole	74	30	40	31	34	28
Years since starting AI therapy
Median	1.2		1.1		1.3
Years since last menstrual period
Median	9.4		9.9		8.8
Weight, kg
Median	79.0		79.8		77.3
Fish consumption
Mean total servings per week
Baseline	1.6		1.7		1.5
Week 6	1.7		1.9		1.4
Week 12	2.1		2.0		2.2
Week 24	1.7		2.0		1.5

Abbreviations: AI, aromatase inhibitor; O3-FA, omega-3 fatty acid.

^*Patient characteristics were well balanced by arm for all factors shown except location of joint pain and black race.

^†Percent columns sum to > 100% because patients could report > one location of joint pain.